{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:12:21Z","timestamp":1776643941237,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T00:00:00Z","timestamp":1249516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2407-9-272","type":"journal-article","created":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T09:13:29Z","timestamp":1249636409000},"source":"Crossref","is-referenced-by-count":40,"title":["Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity"],"prefix":"10.1186","volume":"9","author":[{"given":"Pierre P","family":"Major","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,6]]},"reference":[{"key":"1606_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001, 27: 165-176. 10.1053\/ctrv.2000.0210.","journal-title":"Cancer Treat Rev"},{"key":"1606_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322\/canjclin.57.1.43.","journal-title":"CA Cancer J Clin"},{"issue":"20 pt 2","key":"1606_CR3","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006, 12 (20 pt 2): 6243s-6249s. 10.1158\/1078-0432.CCR-06-0931.","journal-title":"Clin Cancer Res"},{"key":"1606_CR4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, et al: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998, 16: 593-602.","journal-title":"J Clin Oncol"},{"key":"1606_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000, 88: 1082-1090. 10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z.","journal-title":"Cancer"},{"key":"1606_CR6","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, et al: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004, 100: 2613-2621. 10.1002\/cncr.20308.","journal-title":"Cancer"},{"key":"1606_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004, 96: 879-882.","journal-title":"J Natl Cancer Inst"},{"key":"1606_CR8","volume-title":"Poster presented at: Primary Therapy of Early Breast Cancer 9th International Conference; 26\u201329","author":"M Kaminski","year":"2005","unstructured":"Kaminski M, Rosen LS, Gordon D, Zheng M, Hei Y-M: Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. Poster presented at: Primary Therapy of Early Breast Cancer 9th International Conference; 26\u201329. 2005, Abstract 107, January ; St. Gallen, Switzerland"},{"key":"1606_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA: Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004, 42: 164-175. 10.1097\/01.mlr.0000108746.69256.45.","journal-title":"Med Care"},{"key":"1606_CR10","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007, 110: 1860-1867. 10.1002\/cncr.22991.","journal-title":"Cancer"},{"key":"1606_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005, 97: 59-69.","journal-title":"J Natl Cancer Inst"},{"key":"1606_CR12","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","volume":"89","author":"JE Brown","year":"2003","unstructured":"Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE: Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer. 2003, 89: 2031-2037. 10.1038\/sj.bjc.6601437.","journal-title":"Br J Cancer"},{"key":"1606_CR13","doi-asserted-by":"crossref","first-page":"475s","DOI":"10.1200\/jco.2006.24.18_suppl.8529","volume":"24","author":"N Shirina","year":"2006","unstructured":"Shirina N, Coleman RE, Chen YM: Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors [Abstract]. J Clin Oncol. 2006, 24: 475s-Abstract 8529","journal-title":"J Clin Oncol"},{"key":"1606_CR14","volume-title":"Poster presented at: 31st European Society of Medical Oncology (ESMO) Congress; 29 September-3","author":"L Costa","year":"2006","unstructured":"Costa L, Chen Y-M, Shirina N: Breast cancer patients without pain are at risk for skeletal-related events (SREs) and may have better outcomes with zoledronic acid compared with pamidronate. Poster presented at: 31st European Society of Medical Oncology (ESMO) Congress; 29 September-3. 2006, Abstract 178P, October ; Istanbul, Turkey"},{"key":"1606_CR15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996, 335: 1785-1791. 10.1056\/NEJM199612123352401.","journal-title":"N Engl J Med"},{"key":"1606_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/jnci\/93.7.534","volume":"93","author":"RJ Cook","year":"2001","unstructured":"Cook RJ, Major P: Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst. 2001, 93: 534-538. 10.1093\/jnci\/93.7.534.","journal-title":"J Natl Cancer Inst"},{"key":"1606_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<911::AID-SIM544>3.0.CO;2-I","volume":"16","author":"RJ Cook","year":"1997","unstructured":"Cook RJ, Lawless JF: Marginal analysis of recurrent events and a terminating event. Stat Med. 1997, 16: 911-924. 10.1002\/(SICI)1097-0258(19970430)16:8<911::AID-SIM544>3.0.CO;2-I.","journal-title":"Stat Med"},{"key":"1606_CR18","volume-title":"The Statistical Analysis of Recurrent Events","author":"RJ Cook","year":"2007","unstructured":"Cook RJ, Lawless JF: The Statistical Analysis of Recurrent Events. 2007, New York: Springer Science-Business Media, LLC"},{"key":"1606_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3816\/SCT.2005.n.017","volume":"2","author":"PP Major","year":"2005","unstructured":"Major PP, Cook RJ, Chen B-L, Zheng M: Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther. 2005, 2: 234-240. 10.3816\/SCT.2005.n.017.","journal-title":"Support Cancer Ther"},{"issue":"suppl 1","key":"1606_CR20","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/00000421-200212001-00003","volume":"25","author":"PP Major","year":"2002","unstructured":"Major PP, Cook R: Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol. 2002, 25 (suppl 1): S10-S18. 10.1097\/00000421-200212001-00003.","journal-title":"Am J Clin Oncol"},{"issue":"suppl 3","key":"1606_CR21","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.breast.2007.10.005","volume":"16","author":"L Costa","year":"2007","unstructured":"Costa L: Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast. 2007, 16 (suppl 3): S16-S20. 10.1016\/j.breast.2007.10.005.","journal-title":"Breast"},{"key":"1606_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","volume":"6","author":"V Hirsh","year":"2004","unstructured":"Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ: Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004, 6: 170-174. 10.3816\/CLC.2004.n.030.","journal-title":"Clin Lung Cancer"},{"key":"1606_CR23","volume-title":"Poster presented at: Primary Therapy of Early Breast Cancer 9th International Conference; 26\u201329","author":"M Zheng","year":"2005","unstructured":"Zheng M, Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Apffelstaedt J, Hussein M, Hei YJ, Coleman R: Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases. Poster presented at: Primary Therapy of Early Breast Cancer 9th International Conference; 26\u201329. 2005, January ; St. Gallen, Switzerland. Poster 104"},{"key":"1606_CR24","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, et al: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005, 23: 4925-4935. 10.1200\/JCO.2005.06.091.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-9-272\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T08:02:28Z","timestamp":1590048148000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-9-272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,6]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-9-272","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,6]]},"article-number":"272"}}